Janux Therapeutics Craters 53% On Prostate Cancer Update; Is It An 'Overreaction'?

BREAKING: Nasdaq Leads As Stocks Open HigherJanux Therapeutics (JANX) stock crashed Tuesday in what one analyst called an "overreaction" to the biotech company's updated test results for a prostate cancer treatment.The company tested its drug, JANX007, in patients with castration-resistant prostate cancer who had received a median of four prior treatments. Of the 27 patients who could be evaluated, 30% responded to the treatment. That's down from 50% in the previous update a year ago. But the earlier analys ...